Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

AusBiotech and Proto Axiom partner on investor-focused life sciences programs

AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...

The University of Sydney formalises cervical cancer elimination partnership

The success of a cervical cancer elimination program has led to the signing of a memorandum of...

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Content from other channels on our network

HVAC&R behind the scenes of food: the systems, skills and standards shaping the next decade

Machinery Regulation will be Mandatory in Less Than a Year — Are You Ready?

Swisslog's multi-temperature automation modernises cold storage and logistics

Reading Between the Lines: A Smarter Way to Verify Allergen Safety

Clariant achieves EU approval for renewable additives in food-contact plastics

CSIRO and AMRF Connect partner on advanced manufacturing program

Quantum Edge: redefining secure industrial wireless for critical infrastructure

Circular connectors: small components playing a big role in Australian industry

Australian researchers create graphene from peanut waste

Banksia Minerals gets $5m for critical energy mineral processing

Sustainability Business Live: where compliance, risk and commercial strategy come together

$10m project to safeguard WA water supplies

Supermarket giant now powered using 100% renewables

CAWSYD26 to spotlight local climate solutions

Chip makes pH measurements easier